Increased COVID-19 Risk in Patients With Cancer

Patients with cancer are at increased risk of infection with severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, according to a medical records review of patients with cancer at a hospital in Wuhan, China."Patients with cancer from the epicenter of a viral epidemic harbored a higher risk of SARS-CoV-2 infection… compared with the community. However, fewer than half of these infected patients were undergoing active treatment for their cancers," note the investigat...
Continue reading

Anlotinib Improves Survival in Advanced NSCLC Subtypes

In patients with previously treated advanced non-small cell lung cancer (NSCLC), anlotinib increases progression-free survival in squamous cell carcinoma (SCC) and improves both overall and progression-free survival in adenocarcinoma, according to a subgroup analysis of a phase 3 trial.Treatment selection for NSCLC has become largely dependent on histological subtype. In the ALTER0303 trial, anlotinib, a multitargeted tyrosine kinase inhibitor (TKI), showed significant survival benefits among pa...
Continue reading

Pembro/Pemetrexed-Platinum: How Does It Affect Patient QOL?

In patients with previously untreated, metastatic, non-squamous non-small cell lung cancer (NSCLC), pembrolizumab plus pemetrexed-platinum has proven to be an effective treatment compared with pemetrexed-platinum alone in increasing the proportion of patients who experience a complete or partial response, as shown in the KEYNOTE-189 study. Based on the results of this study, the FDA recently approved a new indication for pemetrexed in this combination for the first-line treatment ...
Continue reading

Atezolizumab Plus nab-Paclitaxel and Carboplatin FDA Approved for Metastatic NSCLC

Atezolizumab (Tecentriq®, Genentech Inc.) in combination with nab-paclitaxel and carboplatin is now FDA approved as first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Atezolizumab, previously approved to treat extensive-stage small cell lung cancer, metastatic urothelial carcinoma, and metastatic triple-negative breast cancer, works as a monoclonal antibody and stimulates the immune system by block...
Continue reading

Osimertinib for EGFR-Mutated Advanced NSCLC: An Interview with Suresh S. Ramalingam, MD

The treatment of advanced-stage non-small cell lung cancer (NSCLC) has improved steadily in the past few years, and individualized therapy for patients with mutations in the epidermal growth factor receptor (EGFR) is applied in routine clinical practice. While EGFR-mutated NSCLC is effectively treated with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, there is a need to develop more effective treatments to improve outcomes in these patients. In a study now published in The Ne...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.